High-coverage targeted lipidomics could reveal lipid alterations and evaluate therapeutic efficacy of membranous nephropathy

Table 4 Correlation between 11 lipids selected and therapeutic effect of TCM

Name	Model 1		Model 2		Model 3		Model 4
Name	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
TG52:0-FA20:0	0.602 (0.385, 0.941)	0.026	0.575 (0.360, 0.920)	0.021	0.577 (0.359, 0.926)	0.023	0.636 (0.384, 1.053)	0.078
TG54:2-FA20:0	0.594 (0.382, 0.922)	0.020	0.573 (0.362, 0.906)	0.017	0.572 (0.360, 0.910)	0.018	0.629 (0.384, 1.028)	0.064
TG55:3-FA18:2	0.565 (0.353, 0.904)	0.017	0.573 (0.352, 0.933)	0.025	0.581 (0.350, 0.963)	0.035	0.624 (0.354, 1.099)	0.103
TG55:4-FA18:2	0.557 (0.349, 0.888)	0.014	0.565 (0.349, 0.914)	0.020	0.568 (0.346, 0.931)	0.025	0.619 (0.362, 1.061)	0.081
TG55:5-FA18:2	0.581 (0.369, 0.916)	0.019	0.575 (0.358, 0.922)	0.022	0.578 (0.357, 0.935)	0.026	0.624 (0.376, 1.034)	0.067
TG56:2-FA20:0	0.537 (0.339, 0.851)	0.008	0.533 (0.332, 0.856)	0.009	0.532 (0.330, 0.860)	0.010	0.576 (0.347, 0.958)	0.033
TG56:2-FA20:1	0.517 (0.322, 0.832)	0.007	0.529 (0.327, 0.855)	0.009	0.528 (0.322, 0.865)	0.011	0.554 (0.316, 0.971)	0.039
TG56:3-FA20:0	0.540 (0.337, 0.865)	0.010	0.541 (0.332, 0.881)	0.014	0.536 (0.328, 0.877)	0.013	0.586 (0.350, 0.981)	0.042
TG56:4-FA18:2	0.522 (0.324, 0.842)	0.008	0.536 (0.328, 0.876)	0.013	0.529 (0.319, 0.878)	0.014	0.573 (0.325, 1.010)	0.054
TG56:5-FA20:2	0.565 (0.353, 0.904)	0.007	0.520 (0.318, 0.849)	0.009	0.515 (0.312, 0.850)	0.009	0.540 (0.306, 0.953)	0.033
TG56:9-FA20:5	0.557 (0.349, 0.888)	0.131	0.612 (0.368, 1.016)	0.057	0.617 (0.367, 1.036)	0.068	0.688 (0.356, 1.330)	0.266

ISSN: 1743-7075